Alaunos Therapeutics, Inc. (TCRT)
NASDAQ: TCRT · Real-Time Price · USD
2.420
0.00 (0.00%)
May 22, 2026, 4:00 PM EDT - Market closed
Alaunos Therapeutics Employees
Alaunos Therapeutics had 1 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
1
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$3,000
Profits / Employee
-$4,215,000
Market Cap
5.86M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1 | 0 | - | 1 | 0 |
| Dec 31, 2024 | 1 | 0 | - | 1 | 0 |
| Dec 31, 2023 | 1 | -33 | -97.06% | 1 | 0 |
| Dec 31, 2022 | 34 | -7 | -17.07% | 34 | 0 |
| Dec 31, 2021 | 41 | -65 | -61.32% | 41 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 41 |
| CollPlant Biotechnologies | 39 |
| Aptevo Therapeutics | 33 |
| BiomX | 20 |
| Virax Biolabs Group | 19 |
| FibroBiologics | 15 |
| TransCode Therapeutics | 12 |
| XTL Biopharmaceuticals | 10 |
TCRT News
- 7 days ago - Alaunos Therapeutics reports updated preclinical data from ALN1003 mouse studies - TheFly
- 7 days ago - Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models - GlobeNewsWire
- 10 days ago - Alaunos Therapeutics Quarterly report: Q1 2026 - Filings
- 21 days ago - Valion Bio Appoints Melinda Lackey as General Counsel - PRNewsWire
- 7 weeks ago - Alaunos Therapeutics Annual report: Q4 2025 - Filings
- 3 months ago - Alaunos Therapeutics reports ‘positive’ proof-of-concept data for ALN1003 - TheFly
- 3 months ago - Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders - GlobeNewsWire
- 6 months ago - Alaunos Therapeutics Quarterly report: Q3 2025 - Filings